Clinical Efficacy and Safety of Thoracoscopic Talc Pleurodesis in Malignant Pleural Effusions

Kolschmann, Steffen; Ballin, Arndt; Gillissen, Adrian

doi:10.1378/chest.128.3.1431

Cited by 99 publications

(63 citation statements)

References 24 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Talc has been reported as safe and efficacious for pleurodesis [15][16][17][18][19][20][21][22][23]. A Cochrane review reported that pleurodesis with talc provided the highest relative chance of MPE nonrecurrence when compared with bleomycin, tetracycline, mustine or chest-tube drainage alone [24].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients

Hirata¹,

Yonemori

Hirakawa³

et al. 2011

Eur Respir J

View full text Add to dashboard Cite

This study retrospectively compared long-term outcomes between two groups of breast cancer patients with malignant pleural effusion (MPE): those receiving only systemic therapy (ST) and those receiving ST following initial pleurodesis (P-ST).We identified 180 breast cancer patients from the National Cancer Center Hospital (Tokyo, Japan) database who had received ST and P-ST as an initial treatment for MPE between 1997 and 2008 for study inclusion. Pleural progression-free survival (PPFS) was defined as the time from ST in the ST group and from pleurodesis in the P-ST group to the first observation of pleural progression or death from any cause.Of the 180 patients, 78 received ST and 102 received P-ST after MPE diagnosis. Median duration of follow-up was 12.7 months (range 0.9-80.1 months). Median PPFS for the ST group and the P-ST group was 4.1 and 8.5 months, respectively. The difference in PPFS between the two groups was statistically significant (p,0.001) and the hazard ratio after adjusting for prognostic factors in the P-ST group relative to the ST group was 0.24.Our results suggest that the efficacy of P-ST may be superior to that of ST alone with respect to local control of pleural effusions in breast cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients

Hirata¹,

Yonemori

Hirakawa³

et al. 2011

Eur Respir J

View full text Add to dashboard Cite

show abstract

“…In the study of Kolschmann et al, the success rate of thoracoscopic pleurodesis has been reported as 82.6% and type of primary malignancy had no significant influence on success. (27) Although the mean duration of hospitalization was not long in our study, the range was large. Accompanying diseases and underlying malignancy might be responsible from that finding.…”

Section: Discussion:-mentioning

confidence: 59%

The Efficacy and Safety of Medical Thoracoscopy in Differential Diagnosis of Pleural Effusions.

Uğurlu¹,

Altınışık²,

Yildiz³

et al. 2016

IJAR

View full text Add to dashboard Cite

“…Reported success rates for videothoracoscopic talc pleurodesis range from 84% to 95% [66][67][68][69][70][71][72]. These figures appear to be remarkably higher that those observed after bedside instillation of talc [68,70] or other agents [63,79].…”

Section: Malignant Pleural Effusionmentioning

confidence: 99%

Nonintubated Videothoracoscopic Operations in Thoracic Oncology

Mineo¹,

Tacconi²

2014

J de Chirurgie

View full text Add to dashboard Cite

show abstract

Clinical Efficacy and Safety of Thoracoscopic Talc Pleurodesis in Malignant Pleural Effusions

Cited by 99 publications

References 24 publications

Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients

Efficacy of pleurodesis for malignant pleural effusions in breast cancer patients

The Efficacy and Safety of Medical Thoracoscopy in Differential Diagnosis of Pleural Effusions.

Nonintubated Videothoracoscopic Operations in Thoracic Oncology

Contact Info

Product

Resources

About